Science-led insight on therapeutic use, formulations, and clinical best practice.
In the first of a new three-part series, Graham Woodward, Chief Medical Officer at Releaf, sat down with Business of Cannabis to discuss what it takes to scale a medical cannabis clinic from three patients to tens of thousands in just two years.
SynBiotic SE, once one of the largest and most promising cannabis companies in Germany, has announced plans to file for insolvency and had its shares suspended on the Xetra and Frankfurt stock exchanges.
Dr. Julian Wichmann, MD, Co-Founder and CEO of Bloomwell GmbH Germany has, without question, the most progressive regulation of medical cannabis in the EU.
UK medical cannabis patients have been told that they’ll have access to a six-month stockpile of Bedrolite, following weeks of uncertainty in the wake of Bedrocan’s collapse.
UK medical cannabis cultivator Glass Pharms has partnered with leading clinic Releaf to bring cannabis containing meaningful levels of THCV (Tetrahydrocannabivarin), a cannabinoid linked to reduced appetite in emerging research, to patients in the UK for the first time since 1973.
Spain’s medical cannabis framework will finally start reaching patients over the coming days and weeks, marking a significant milestone in a four-year battle for access.
Frances’ incoming medical cannabis framework is expected to take the final step before it can be signed into law in the ‘coming weeks’.
Bedrocan’s Dutch entities have officially been declared bankrupt, leaving stocks of life-saving medicinal cannabis in the hands of court-appointed administrators who cannot release them.
Thousands of Dutch patients are facing a 10-month supply gap for medically essential Bedrocan products, including varieties clinicians consider irreplaceable for children with treatment-resistant epilepsy.
